Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Phase 2

Withdrawn

• Conditions: Hepatocellular Carcinoma
• Interventions: Drug: Cadonilimab+Lenvatinib

• Registration Number: NCT06361758
• Lead Sponsor: Shanghai Zhongshan Hospital

Brief Summary

This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and safety of lenvatinib in combination with cadonilimab as second-line therapy in subjects with advanced hepatocellular carcinoma (HCC) who failed first-line standard therapy of immunotheray and antiangiogenic therapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-04-08
• Study First Submitted QC: 2024-04-08
• Study First Posted: 2024-04-12
• Study Start: 2024-05-31
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-20
• Last Update Posted: 2025-05-23
• Primary Completion: 2026-05-31
• Study Completion: 2027-05-31

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Sign a written informed consent and be able to comply with the visit and related procedures required by the study protocol
• Age 18-75 years old, Male of Female
• ECOG PS 0-1
• histologically/cytologically or clinically (according to Chinese guidelines for primary liver cancer diagnosis and treatment (2022) criteria) confirmed initial diagnosis of HCC
• Not suitable for radical surgery and/or local treatment, BCLC stage C or stage B who failed local treatment
• Patients who progressed on first-line standard system therapy (Atezolizumab plus bevacizumab, sintilimab combined with bevacizumab, or Camrelizumab and Apatinib, only these three regimenes) or with intolerable toxicity ( except for immunotherapy intolerance)
• Child Pugh A-B7
• Expected survival time≥12 weeks
• At least one measurable lesion (RECIST 1.1)
• Enough organ and bone marrow function

Exclusion Criteria

• Fibrolamellar sarcomatoid or mixed cholangiocarcinoma-hepatocellular carcinoma.
• Other anti-tumor therapies have been received after first-line systemic anti-tumor therapy.
• Have history of hepatic encephalopathy, or a history of liver transplantation.
• There are clinical symptoms requiring drainage of pleural fluid, ascites, pericardial effusion.
• People with acute or chronic active hepatitis B or hepatitis C, hepatitis B virus (HBV) DNA > 2000IU/ml or 10^4 copies /ml; Hepatitis C virus (HCV) RNA > 10^3 copies /ml; Hepatitis B surface antigen (HbsAg) and anti-HCV antibodies were both positive.
• Central nervous system metastasis.
• Previous bleeding from esophageal or fundus varices due to portal hypertension occurred within 6 months.
• Autoimmune immune disease.
• HIV infection.
• Pregnant women.
• The presence of any serious or uncontrolled systemic disease.
• Other acute or chronic diseases, psychiatric disorders or abnormal laboratory test values that may lead to the following results: increasing the risk associated with research or drug administration, or interfering with the interpretation of research results. The Investigator considers that there are other potential risks that are not suitable for participation in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Cadonilimab+Lenvatinib	Cadonilimab+Lenvatinib	-

Primary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR) per RECIST v1.1	Up to two years	Defined as the proportion of patients who achieved complete response (CR) and partial response (PR) according to RECIST v1.1.

Secondary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR) per mRECIST	Up to two years	Defined as the proportion of patients who achieved complete response (CR) and partial response (PR) according to mRECIST.
Disease control Rate (DCR)	Up to two years	Defined as the proportion of patients who achieved complete response (CR), partial response (PR), and stable disease (SD) according to RECIST v1.1 and mRECIST respectively.
Duration of response (DoR)	Up to two years	Defined as the time from the first dose to disease progression or death in patients who achieve complete or partial response.
Progression-Free-Survival (PFS)	Up to two years	Defined as the time between signing the informed consent form to the disease progression (according to RECIST v1.1 criteria) or death due to any cause.
Overall survival Overall survival (OS)	Up to three years	Defined as the time between the first dose to death due to any causes.
Incidence of Adverse Events	Up to two years	Adverse events (AEs) ; serious adverse events (SAEs); Treatment related Adverse events (TRAEs); Use NCI-CTCAE version 5.0 for classification and grading.

Trial Locations

Locations (3)

Zhongshan Hospital, Fudan University; 🇨🇳 Shanghai, Shanghai, China

Sun Yat-sen University Cancer Center); 🇨🇳 Guangzhou, China

Eastern Hepatobiliary Surgery Hospital; 🇨🇳 Shanghai, China